Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16527742 | 1.00 | DGAT1 (0.53) | DGAT1IDO1HDAC3HDAC11HDAC8 | |
| SCHEMBL16527560 | 0.95 | IDO1 (0.60) | DGAT1IDO1 | |
| SCHEMBL16542660 | 0.95 | IDO1 (0.60) | DGAT1IDO1 | |
| SCHEMBL16527593 | 0.94 | DGAT1 (0.56) | DGAT1IDO1HDAC3 | |
| SCHEMBL16527594 | 0.94 | DGAT1 (0.56) | DGAT1IDO1HDAC3 | |
| SCHEMBL16542737 | 0.91 | GCGR (0.50) | DGAT1IDO1 | |
| SCHEMBL16527620 | 0.91 | GCGR (0.50) | DGAT1IDO1 | |
| SCHEMBL16527590 | 0.90 | DGAT1 (0.51) | DGAT1 | |
| SCHEMBL16527711 | 0.90 | DGAT1 (0.49) | DGAT1IDO1 | |
| SCHEMBL16527419 | 0.90 | DGAT1 (0.47) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104254519-B | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as the active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-20 | — | — | CN | claimed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | claimed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | claimed |
| CN-104254519-A | Novel beta-alanine derivative, pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | KOREA RES INST CHEM TECH | 2014-12-31 | — | — | CN | claimed |
| US-9321728-B2 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-26 | — | — | US | disclosed |
| CN-104254519-B | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as the active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-04-20 | — | — | CN | disclosed |
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| EP-2842938-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-03-04 | — | — | EP | disclosed |
| CN-104254519-A | Novel beta-alanine derivative, pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | KOREA RES INST CHEM TECH | 2014-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329504-A1 | NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | DGAT1, GOT1, ACAT2 | DGAT1 1/4885IDO1 1446/4885HDAC3 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.